PanamaTuberculosis profile
Population  2016 4 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.2–0.25) 5.5 (4.9–6.1)
Mortality (HIV+TB only) 0.052 (0.036–0.07) 1.3 (0.89–1.7)
Incidence  (includes HIV+TB) 2.2 (1.7–2.8) 55 (42–70)
Incidence (HIV+TB only) 0.25 (0.16–0.36) 6.2 (4–8.9)
Incidence (MDR/RR-TB)** 0.096 (0.057–0.14) 2.4 (1.4–3.4)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.12 (0.088–0.15) 0.65 (0.48–0.81) 0.76 (0.57–0.95)
Males 0.13 (0.099–0.16) 1.3 (1–1.7) 1.5 (1.1–1.8)
Total 0.25 (0.19–0.31) 2 (1.5–2.5) 2.2 (1.7–2.8)
TB case notifications, 2016  
Total cases notified 1 858
Total new and relapse 1 787
          - % tested with rapid diagnostics at time of diagnosis 24%
          - % with known HIV status 96%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 59%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.12 (0.09–0.16)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 190 11%
          - on antiretroviral therapy 190 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  68
(41–94)
Estimated % of TB cases with MDR/RR-TB 2.9% (1.4–4.5) 17% (8.9–29)  
% notified tested for rifampicin resistance 21% 31% 589
MDR/RR-TB cases tested for resistance to second-line drugs   19
Laboratory-confirmed cases MDR/RR-TB: 49, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 49, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 82% 1 646
Previously treated cases, excluding relapse, registered in 2015 49% 98
HIV-positive TB cases registered in 2015 66% 209
MDR/RR-TB cases started on second-line treatment in 2014 50% 20
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 2.3
Funding source: 31% domestic, 27% international, 43% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data